CAPTRUST Financial Advisors
BLRX

CAPTRUST Financial Advisors’s BioLineRX BLRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-502
Closed -$4.29K – 2364
2024
Q4 		$4.29K Buy
502
+98
+24% +$1.45K ﹤0.01% 2287
2024
Q3 		$8.67K Buy
+404
New +$11.1K ﹤0.01% 2275
2022
Q3 		– Sell
-29
Closed -$1K – 2305
2022
Q2 		$1K Hold
29
– – ﹤0.01% 4632
2022
Q1 		$2K Buy
+29
New +$2.02K ﹤0.01% 4461

Other funds holding BLRX

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAPTRUST Financial Advisors's BLRX Position: Q1 2025 in Review

CAPTRUST Financial Advisors sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 502 shares — an estimated $4.29K sold.

CAPTRUST Financial Advisors first reported a position in BLRX in Q1 2022 and held it in 4 quarters. The position peaked at $8.67K in Q3 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

  • CAPTRUST Financial Advisors reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 502 BioLineRX shares in Q1 2025, an estimated $4.29K.
  • CAPTRUST Financial Advisors first reported a position in BioLineRX in Q1 2022 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's BioLineRX position peaked at $8.67K in Q3 2024.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2025, filed 15 May 2025.